Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Abivax will report H1 earnings Sept. 21; analysts expect a $1.08 loss/share and $1.86M revenue.
Stocks · News reference
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis
Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Amer Sports Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiate: Buy—Abivax ($155), Amer Sports ($42) and more
Goldman Sachs Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $155
Goldman Sachs analyst Rajan Sharma initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $155.
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
Bristol Myers announced positive two-year results from the POETYK PsA-2 study showing Sotyktu (deucravacitinib) maintained durable efficacy and consistent safety through week 104. The drug generated $156 million in H1 2026 revenues, up 24% year-over-year, with potential for further expansion into lupus and Sjögren's disease indications.
Bitcoin Tops $80,000, S&P 500 Slips as Yields Reclaim 5%: Stock Market Today
Crypto-linked equities ripped higher as Bitcoin cleared $80,000, but the S&P 500 slipped with the 10-year Treasury yield back above 5%.
Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape
The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.